PERSONALIZED DRUG RESPONSE: IMPLEMENTATION and EVALUATION in CKD
PERSONALIZED DRUG RESPONSE: IMPLEMENTATION and EVALUATION in CKD
批准号:
10076730
负责人:
金额:
$12.49万
依托单位国家:
英国
项目类别:
EU-Funded
财政年份:
2023
资助国家:
英国
项目状态:
未结题
起止时间:
2023 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Chronic Kidney Disease (CKD) is one of the major causes of death in high income countries and its prevalence is growing rapidly. New therapies for the treatment of CKD have shown clear efficacy at a population level. Yet, individual patients respond differently with many patients showing suboptimal efficacy. This indicates that a ‘one size fits all’ approach is no longer sustainable. Currently there are no validated pharmacodynamic biomarkers in CKD that aid in guiding optimal therapy for individual patients. Furthermore, there remains a large gap between biomarker research and actual implementation of biomarker based care in daily clinical practice. Thus, there is an urgent need to validate and translate biomarkers as tools for daily clinical practice. PRIME-CKD has a unique advantage to address this challenge as it builds on recently discovered pharmacodynamic biomarkers for CKD treatment, and has access to a vast amount of clinical data, bio-samples. PRIME CKD will: 1) Provide a breakthrough in the pharmacotherapy of CKD with the validation and implementation of pharmacodynamic biomarkers which will advance personalized medicine. 2) Scientifically validate innovative clinical trial elements, pipelines and qualification procedures that can be used by researchers, diagnostics industries and regulatory authorities. 3) Establish a Stakeholder Network to truly engage patients, clinicians and other stakeholders in implementation of personalized medicines 4) Develop a roadmap for biomarker use in daily clinical practice for the optimal treatment of CKD. These results will enable clinicians to match patients with CKD with the most effective available drug within the shortest possible timeframe leading to less disease burden and progression of disease, enhanced quality of life and increased cost-efficiency. PRIME-CKD results will thus unlock the potential of biomarkers in healthcare and close the gap between biomarker research and clinical use in daily practice.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
不同功能基团的电中性Drug-Free纳米颗粒的构建及克服肿瘤耐药的研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:杨胜彩
-
依托单位:
Drug-ADR-Pathway复合网络构建及ADR分子机制研究
-
批准号:61372188
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:陈秀杰
-
依托单位:
Drug-pHLA对接指纹图谱库的构建及HLA介导SADR的预测方法研究
-
批准号:61073135
-
项目类别:面上项目
-
资助金额:10.0万元
-
批准年份:2010
-
负责人:梅虎
-
依托单位:
新型药物传输系统drug-LDHs 复合纳米粒子的可控制备及其微结构对缓控释性能的调控
-
批准号:20776012
-
项目类别:面上项目
-
资助金额:31.0万元
-
批准年份:2007
-
负责人:张慧
-
依托单位:
用Drug-Western法分离恶性疟原虫cDNA编码的青蒿素类药物结合蛋白
-
批准号:30070681
-
项目类别:面上项目
-
资助金额:14.0万元
-
批准年份:2000
-
负责人:程远国
-
依托单位: